These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7551222)

  • 1. Development of vaccines based on formulations containing nonionic block copolymers.
    Brey RN
    Pharm Biotechnol; 1995; 6():297-311. PubMed ID: 7551222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of action of nonionic block copolymer adjuvants.
    Hunter RL; McNicholl J; Lal AA
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S95-8. PubMed ID: 7865341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses.
    Lanier JG; Newman MJ; Lee EM; Sette A; Ahmed R
    Vaccine; 1999 Oct; 18(5-6):549-57. PubMed ID: 10519946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations.
    Todd CW; Pozzi LA; Guarnaccia JR; Balasubramanian M; Henk WG; Younger LE; Newman MJ
    Vaccine; 1997 Apr; 15(5):564-70. PubMed ID: 9160526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly.
    Newman MJ; Todd CW; Lee EM; Balusubramanian M; Didier PJ; Katz JM
    Mech Ageing Dev; 1997 Feb; 93(1-3):189-203. PubMed ID: 9089583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective polymer adjuvants for sustained delivery of protein subunit vaccines.
    Adams JR; Haughney SL; Mallapragada SK
    Acta Biomater; 2015 Mar; 14():104-14. PubMed ID: 25484331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of nonionic block copolymers in vaccines and therapeutics.
    Newman MJ; Actor JK; Balusubramanian M; Jagannath C
    Crit Rev Ther Drug Carrier Syst; 1998; 15(2):89-142. PubMed ID: 9592626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of adjuvant-active nonionic block copolymers.
    Todd CW; Balusubramanian M; Newman MJ
    Adv Drug Deliv Rev; 1998 Jul; 32(3):199-223. PubMed ID: 10837645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.
    Elliott SL; Pye S; Le T; Mateo L; Cox J; Macdonald L; Scalzo AA; Forbes CA; Suhrbier A
    Vaccine; 1999 Apr; 17(15-16):2009-19. PubMed ID: 10217601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vaccine models: multiple delivery systems employing tetanus toxoid.
    Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR
    Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants in veterinary vaccines: modes of action and adverse effects.
    Spickler AR; Roth JA
    J Vet Intern Med; 2003; 17(3):273-81. PubMed ID: 12774966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents.
    Eng NF; Garlapati S; Gerdts V; Potter A; Babiuk LA; Mutwiri GK
    Curr Drug Deliv; 2010 Jan; 7(1):13-20. PubMed ID: 19863483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copolymer adjuvants in malaria vaccine development.
    Hunter RL; Lal AA
    Am J Trop Med Hyg; 1994; 50(4 Suppl):52-8. PubMed ID: 8172332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.
    Coulter A; Wong TY; Drane D; Bates J; Macfarlan R; Cox J
    Vaccine; 1998 Jul; 16(11-12):1243-53. PubMed ID: 9682385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic development of a block copolymer adjuvant for trivalent influenza virus vaccine.
    Todd CW; Lee E; Balusubramanian M; Shah H; Henk WG; Younger LE; Newman MJ
    Dev Biol Stand; 1998; 92():341-51. PubMed ID: 9554290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
    Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity.
    Khademi F; Derakhshan M; Yousefi-Avarvand A; Najafi A; Tafaghodi M
    Microb Pathog; 2018 Dec; 125():507-513. PubMed ID: 30352265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.